Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -480.19M | -525.91M | -519.02M | -522.28M | -508.80M |
| Total Depreciation and Amortization | 10.15M | 10.27M | 10.29M | 10.19M | 9.87M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 118.14M | 155.67M | 147.98M | 142.41M | 136.33M |
| Change in Net Operating Assets | -66.67M | -17.18M | 11.88M | 12.95M | -10.68M |
| Cash from Operations | -418.58M | -377.15M | -348.88M | -356.74M | -373.28M |
| Capital Expenditure | -3.23M | -4.01M | -5.78M | -6.32M | -9.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 348.33M | 218.00M | 131.35M | 26.26M | 116.52M |
| Cash from Investing | 345.09M | 213.99M | 125.57M | 19.94M | 107.15M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99.16M | 125.76M | 185.75M | 289.91M | 226.82M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99.16M | 125.76M | 185.75M | 289.91M | 226.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.67M | -37.40M | -37.57M | -46.88M | -39.31M |